An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Ztalmy

Chemical Nameganaxolone
Dosage FormSuspension (oral; 50 mg/mL)
Drug ClassModulators
SystemNervous
CompanyMarinus Pharmaceuticals
Approval Year2022

Indication

  • For the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older
Last updated on 4/27/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ztalmy (ganaxolone) Prescribing Information. 2022Marinus Pharmaceuticals, Inc., Radnor, PA
Document TitleYearSource
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. 2022The Lancet Neurology